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A B S T R A C T
Background: Dysfunctions in the intrinsic clocks are suggested in patients with depressive disorders. The
cryptochrome circadian clocks 1 and 2 (CRY1 and CRY2) proteins modulate circadian rhythms in a cell and
inﬂuence emotional reactions and mood in an individual. The protein kinase C delta binding protein
(PRKCDBP, or CAVIN3), similar to the serum deprivation response protein (SDPR, or CAVIN2), reduces
metabolic stability of the PER2-CRY2 transcription factor complex that plays a role in the circadian rhythm
synchronization. Our aim was to study SDPR, PRKCDBP, CRY1 and CRY2 genetic variants in depressive
disorders.
Methods: The sample included 5910 Finnish individuals assessed with the Munich-Composite International
Diagnostic Interview (M-CIDI) in year 2000. In year 2011, 3424 individuals were assessed again. After genotype
quality control, there were 383 subjects with major depressive disorder, 166 with dysthymia, and 479 with
depressive disorders (major depressive disorder, dysthymia or both), and 4154 healthy controls. A total of 48
single-nucleotide polymorphisms from SDPR, PRKCDBP, CRY1 and CRY2 genes were analyzed using logistic
regression models controlling for age and gender.
Results: The earlier reported association of CRY2 variants with dysthymia was conﬁrmed and extended to
major depressive disorder (q < 0.05). In addition, novel associations of PRKCDBP rs1488864 with depressive
disorders (q=0.02) and with major depressive disorder in speciﬁc (q=0.007) were found.
Limitations: The number of cases was moderate and coverage of PRKCDB was limited.
Conclusions: CRY2 and PRKCDBP variants may be risk factors of major depressive disorder and provide
information for diagnosis.
1. Introduction
Patients with depressive disorders often have not only sleep
disturbances, but also abnormalities in their sleep-wakefulness cycle
or rapid-eye-movement sleep that suggest there are dysfunctions in the
intrinsic clocks generating and maintaining the circadian rhythms.
Concerning the circadian rhythms, a strong repressor during the
evening is irreplaceable to the morning phase in the normal circadian
clock (Ukai-Tadenuma et al., 2008). The cryptochrome circadian clocks
1 and 2 (CRY1 and CRY2) are strong repressors, and their endogenous
properties confer information as a function of time (Edwards et al.,
2016). A delay in transcription of CRY1 via clock-controlled DNA
elements from the CRY1 promoter and a further delay via clock-
controlled DNA elements from the CRY1 intron are the steps that keep
the amplitude of circadian clocks robust (Ukai-Tadenuma et al., 2011).
Therefore, CRY1 and CRY2 are plausible targets of interest. Here,
CRY2 has a key role, as it not only acts as a general repressor, but also
opposes the actions of CRY1 and inhibits CRY1 from accessing to its
DNA targets too early, possibly facilitated by PER proteins (Anand
et al., 2013). Repression by CRY1 is like a homeostatic process with an
autonomous and open-ended action that extends from circadian night
into circadian day. It is the ratio rather than the absolute amounts of
CRY proteins that determines the circadian period, and, e.g., if the
CRY1-to-CRY2 ratio is greater than it is usually is, then the nuclear
import rate of the PER-CRY complex slows down and the circadian
period lengthens (Li et al., 2016). Further, it is only CRY2 however that
can inhibit the activated forms of ARNTL, the key clock protein, while
the CRY1 and PER proteins have no eﬀect (Dardente et al., 2007).
Intriguingly, as the levels of PER2 in the correct phase is far more
critical for the circadian synchronization than PER2 levels as such, the
dimerization of PER2 with CRY1 or with CRY2 may play a role in the
pathogenesis (Chen et al., 2009). It is of note that the interval φ
(alignment diﬀerence) tracks dawn and dusk, and that for the
measurement of alignment the CRY1 and CRY2 proteins give a signal
of the evening hours, whereas the PER1 and PER2 proteins give a
signal of the morning hours in day-active animals, e.g. in sheep
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(Lincoln et al., 2003).
Currently, it is not known, whether the aforementioned dynamics
between PER and CRY proteins holds for humans as well. Here, if it
were to hold, the model built by Aziz Sancar and his coworkers (Ye
et al., 2011, 2014) may provide a key to understanding of the
pathogenesis in mood disorders. The model says that the CRY proteins
are in a dynamic equilibrium with the ARNTL-CLOCK complex on E-
boxes, that in the presence of PER proteins at a suﬃciently high
concentration in the nucleus all CRY proteins become trapped by the
dimerization, and that these dimers cannot bind to the ARNTL-CLOCK
complex on E-boxes (Ye et al., 2011, 2014). Thus, a key to the
pathogenesis may lie in abnormal signals of the evening that are due
to the actions of the CRY1 and CRY2 proteins encoded by CRY1 and
CRY2, respectively, whose genetic variants might therefore associate
with major depressive disorder. Moreover, the CRY1 and CRY2
proteins block the increases in cyclic adenosine monophosphate, which
are driven by activation of G protein-coupled receptors, e.g. those for
dopamine, and the subsequent cascades in the liver (Zhang et al., 2010)
and possibly universally within the organism (O’Neill et al., 2008). It
has been demonstrated that the increases in cyclic adenosine mono-
phosphate and the downstream activation of cyclic-adenosine-mono-
phosphate-responsive element binding protein in the striatum lead to a
depressive-like behavioral phenotype in mice (Park et al., 2005). To
sum up, the CRY1 and CRY2 proteins are hence strategically positioned
to modulate not only circadian rhythms of a cell or a tissue but also to
inﬂuence emotional reactions and mood of the individual.
Beyond, the protein kinase C delta binding protein (PRKCDBP, also
known as CAVIN3) regulates the abundance of PER2 and possibly
CRY2 (Schneider et al., 2012). PRKCDBP increases the strength of
interaction within the PER2-CRY2 complex and reduces their meta-
bolic stability, similar to the serum deprivation response (SDPR, also
known as CAVIN2), and the CAVIN3 gain-of-function lengthens the
circadian period.
Thus, genes SDPR, PRKCDBP, CRY1, and CRY2 are among the key
targets for studying the etiology and genetic mechanisms of mood
disorders. The aim of our present work was therefore to study SDPR
and PRKCDBP genes in major depressive disorder and dysthymia
(chronic depressive disorder). In addition, with more cases identiﬁed in
the year 2011, we wanted to conﬁrm the positive association of CRY2
with dysthymia reported earlier.
2. Methods
2.1. Subjects
Our sample included 5910 individuals who had in year 2000 given
blood samples, taken part to the Munich-Composite International
Diagnostic Interview (M-CIDI) (Wittchen et al., 1998) and ﬁlled in a
self-report on the seasonal variations in mood and behavior adapted
from the Seasonal Pattern Assessment Questionnaire (Rosenthal et al.,
1984). Of these 5910 individuals, 3424 took part in the M-CIDI
interview again in year 2011. The sample is part of the national
Health 2000 survey (Aromaa and Koskinen, 2004) of the Finnish
population aged 30 years and older (n=8028) and its follow-up survey
in the year 2011 (n=7964). The study was approved by the ethics
committees of the National Public Health Institute and the Helsinki
and Uusimaa Hospital District. The study was carried out in accor-
dance with the principles of the Declaration of Helsinki and its
amendments. All participants provided a written informed consent.
2.2. Phenotypes
Phenotypes of interest were major depressive disorder, dysthymia,
and depressive disorders (herein, major depressive disorder, dysthy-
mia, or both). Cases included the participants diagnosed to have a
depressive disorder in year 2000 added with new cases from year 2011.
Healthy controls were free of depressive disorders, anxiety disorders
(panic disorder w/o agoraphobia, generalized anxiety disorder, social
phobia, and/or agoraphobia) and alcohol use disorders (abuse and/or
dependence) in year 2000 and also in year 2011, if they took part in the
follow-up. For depressive and anxiety disorders, the diagnoses were
assessed for the past 12 months and for alcohol use disorders for the
lifetime.
2.3. Gene and SNP selection
Selection of SNPs in SDPR, PRKCDBP, CRY1 and CRY2 was based
on HapMap phase 3 data (http://www.hapmap.org/), and tagging was
done using the Tagger program in the Haploview 4.1 software (Barrett
et al., 2005). The linkage disequilibrium (LD) within the gene and
within 10 kb of their 5′ and 3′ ﬂanking regions, that is, 122 kb for
CRY1 (chr12: 107 375–107 497 kb, GRCh37/hg19 assembly), 56 kb
for CRY2 (chr11:45 859–45 915 kb), 22 kb for PRKCDBP (chr11:
6329–6351 kb) and 33 kb for SDPR (chr2:192 689-192 722), was used
to select tag-SNPs capturing most of the genetic variation. The aim was
to capture all the SNPs having a minor allele frequency (MAF) of > 5%
in the European population (CEU and TSI) in the HapMap database.
The pair-wise r2 was set to ≥0.9 in order to select a tag-SNP among the
SNPs that were in high LD. Ten out of 21 CRY1, 10 out of 34 CRY2 and
3 out of 14 SDPR SNPs fulﬁlled the criterion and were all successfully
included in the genotyping multiplexes. Of the 12 out of 19 PRKCDBP
SNPs fulﬁlling the criterion, 8 were successfully included. In addition
to the aforementioned tag-SNPs, 20 potentially functional CRY1 (12)
and CRY2 (8) variants were selected using Pupasuite,21 Variowatch,22
database of SNPs aﬀecting miR Regulation (dbSMR)23 and microRNA
SNP24 databases, and were included in the study. Supplementary
Table S1 presents all the 53 SNPs that were successfully genotyped in
this study.
2.4. Genotyping
Genomic DNA was isolated from whole blood according to standard
procedures. The SNPs were genotyped at the Institute for Molecular
Medicine Finland (FIMM), Technology Centre, University of Helsinki,
using the MassARRAY iPLEX method (Sequenom, San Diego, CA,
USA) (Jurinke et al., 2002), with excellent success ( > 95%) and
accuracy (100%) rates (Lahermo et al., 2006). For quality control
purposes, positive (CEPH) and negative water controls were included
in each 384-plate. Genotyping was performed blind to phenotypic
information.
314 of 5910 individuals were excluded due to a high missing
genotype rate (i.e. > 0.1). The total genotyping rate in the remaining
individuals was 0.997. Three SNPs turned out to be non-polymorphic
(CRY2 rs35488012, rs117531403 and rs76545099), and two SNPs
were removed because their minor allele frequency was < 0.01 (CRY2
rs3747548, CRY1 rs7294758). Finally, there were 5596 individuals and
48 SNPs for the statistical analyses.
2.5. Statistical analyses
SNP and haplotype statistical analyses were performed using
logistic regression and additive genetic model controlling for age and
gender (unadjusted models in Supplementary Table S3 online) with
PLINK software version 1.07 (Purcell et al., 2007). Only haplotypes
with more than 5% frequency are reported. In order to account for
multiple comparisons, false discovery rate (FDR) q-values (Storey,
2003) were computed to correct for the SNPs and phenotypes analyzed
using stats package in R software version 3.0.0 (R Core Team, 2015).
3. Results
General characteristics of the participants are shown in Table 1, and
L. Kovanen et al. Journal of Affective Disorders 207 (2017) 136–140
137
the genotype frequencies, minor allele frequencies and Hardy-
Weinberg equilibrium (HWE) p-values in the whole sample are
reported in Supplementary Table 1 online (please, see Supplementary
Tables S2–S4 online for the genotype counts of major depressive
disorder, dysthymia and depressive disorders, respectively). All the
single-nucleotide polymorphisms (SNPs) were in HWE (P > 0.01).
Table 2 displays the signiﬁcant (q < 0.05) SNP association results of
the adjusted model. In brief, one PRKCDBP SNP (rs1488864) asso-
ciated both with major depressive disorder (OR=1.6, 95% CI=1.2–2.0,
p=0.0002, q=0.007) and with depressive disorders (OR=1.5, 95%
CI=1.2–1.8, p=0.0009, q=0.02). Seven CRY2 SNPs associated with
dysthymia, major depressive disorder, or depressive disorders. All the
SNP association results are shown in Supplementary Tables S5 and S6
online (adjusted and unadjusted models, respectively).
The haplotype blocks formed are shown in Table 3, the signiﬁcant
(q < 0.05) adjusted haplotype associations in Table 4, and all haplotype
associations in Supplementary Table S7 online. PRKCDBP haplotype
ATTA (rs1488864|rs2947030|rs16911940|rs10839553) associated
with the increased odds for major depressive disorder (OR=1.6,
p=0.0003, q=0.02) and depressive disorders (OR=1.5, p=0.001,
q=0.02). CRY2 haplotype ATGCGGGGCACG (rs7121611|rs7121775|
rs10838524|rs2292913|rs7945565|rs1401419|rs7123390|
rs4755345|rs17787136|rs10838527|rs2292910|rs3824872) asso-
ciated with dysthymia (OR=1.5, p=0.0004, q=0.02).
4. Discussion
CRY2 rs10838524 G allele, rs7121611 A allele, rs7945565 G allele,
rs1401419 G allele and rs3824872 G allele were associated with
dysthymia, which was supported by haplotype analysis. CRY2
rs7123390 G allele and rs2292910 C allele were associated with major
depressive disorder. CRY2 rs7121611 A allele, rs7945565 G allele,
rs1401419 G allele and rs2292910 C allele were associated with
depressive disorders. PRKCDBP rs1488864 A allele was associated
both with major depressive disorder and with depressive disorders
(depressive disorders, dysthymia or both), which were supported by
haplotype analysis.
We have earlier reported four of the SNPs (CRY2 SNPs rs10838524,
rs7121611, rs7945565 and rs1401419) to associate with dysthymia
(Kovanen et al., 2013). During the 11-year follow-up period, the
number of individuals with dysthymia increased from 136 to 186.
The ﬁfth CRY2 tag-SNP rs3824872 now associated with dysthymia is
Table 1
General characteristics of the participants.
Major depressive disorder Dysthymia Depressive disorder
n cases 2000 253 121 328 (46 both diagnosis)
n reassessed in 2011 (%) 164 (64.8) 73 (60.3) 206 (62.8)
male gender % 30.8 31.4 30.5
age 2000 (mean ± s.d. [range]) 47.2 ± 11.9 [30–81] 53.3 ± 13.8 [30–88] 48.8 ± 12.7 [30–88]
n cases 2011 161 58 201 (18 both diagnosis)
male gender % 28.6 37.9 31.8
age 2011 (mean ± s.d. [range]) 54.6 ± 9.9 [41–93] 54.8 ± 10.3 [41–84] 54.9 ± 10.0 [41–93]
n all cases 383 166 479 (70 both diagnosis)
male gender % 29.8 33.7 30.7
age 2000 46.2 ± 11.4 [30–82] 50.6 ± 13.7 [30–88] 47.4 ± 12.2 [30–88]
n controls all 4154 (2456 reassessed in 2011) 4154 (2456 reassessed in 2011) 4154 (2456 reassessed in 2011)
male gender % 43.2 43.2 43.2
age 2000 (mean ± s.d. [range]) 53.5 ± 14.8 [30–97] 53.5 ± 14.8 [30–97] 53.5 ± 14.8 [30–97]
Table 2
Significant (q-value < 0.05) SNP associations of the adjusted model.
Phenotype Gene SNP A1 N OR L95 U95 P-value q-value
Dysthymia CRY2 rs7121611 A 4318 1.59 1.28 1.99 0.00004 0.002
Dysthymia CRY2 rs10838524 G 4317 1.56 1.25 1.95 0.00009 0.003
Dysthymia CRY2 rs7945565 G 4308 1.59 1.28 1.99 0.00004 0.002
Dysthymia CRY2 rs1401419 G 4306 1.59 1.27 1.98 0.00004 0.002
Dysthymia CRY2 rs3824872 T 4319 0.61 0.46 0.82 0.001 0.02
Major depressive disorder PRKCDBP rs1488864 A 4527 1.58 1.24 2.01 0.0002 0.01
Major depressive disorder CRY2 rs7123390 A 4535 0.77 0.65 0.92 0.004 0.05
Major depressive disorder CRY2 rs2292910 A 4534 0.78 0.67 0.93 0.004 0.05
Depressive disorders PRKCDBP rs1488864 A 4623 1.47 1.17 1.84 0.0009 0.02
Depressive disorders CRY2 rs7121611 A 4631 1.25 1.09 1.43 0.002 0.02
Depressive disorders CRY2 rs7945565 G 4619 1.25 1.09 1.43 0.001 0.02
Depressive disorders CRY2 rs1401419 G 4619 1.24 1.08 1.42 0.002 0.03
Depressive disorders CRY2 rs2292910 A 4630 0.79 0.68 0.92 0.002 0.03
A1, Tested allele (minor allele).
N, Number of individuals included in analysis.
OR, Odds ratio.
L95/U95, Upper/Lower bounds of 95% confidence interval.
Table 3
Haplotype blocks estimated.
Gene KB NSNPs SNPs
SDPR 14.4 2 rs7577607|rs10174723
PRKCDBP 8.5 4 rs1488864|rs2947030|rs16911940|rs10839553
CRY2 41.5 12 rs7121611|rs7121775|rs10838524|rs2292913|
rs7945565|rs1401419|rs7123390|rs4755345|
rs17787136|rs10838527|rs2292910|rs3824872
CRY1 4.7 3 rs4964513|rs714359|rs12821586




KB, the kilobase distance spanned by the block.
NSNPs, number of SNPs in the block.
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located downstream of CRY2 gene and upstream of MAPK8IP1 gene.
Earlier, we have also reported the associations of rs10838524 allele G
and rs7123390 allele G in a Finnish sample, and those of rs10838524
allele A, rs10838527 allele G and rs3824872 allele A in a Swedish
sample with winter depression (Lavebratt et al., 2010). In addition,
CRY2 rs10838524 A allele has been associated with bipolar disorder
with rapid cycling, and CRY2 haplotype GGAC (of SNPs rs10838524,
rs7123390, rs10838527 and rs3824872) was under-represented
among the rapid-cycling cases (Sjoholm et al., 2010). Furthermore,
CRY2 rs10838524 A allele has been associated with greater chronicity
of depressive symptoms (Fiedorowicz et al., 2012), and weak associa-
tions of CRY2 rs10838524 G allele, and of haplotype GG of rs10838524
and rs7123390 with depressed female patients with early morning
awakening have been reported (Utge et al., 2010). However, there are
also reports of no association of CRY2 rs10838524 with major
depressive disorder (Hua et al., 2014) and of no association of
rs7121611 and rs2292910 with major depressive disorder or bipolar
disorder (Soria et al., 2010).
Concerning CRY2, there is currently no information whether the
SNPs we analyzed have any functional relevance to mood or behavior.
Of the 12 SNPs forming the dysthymia-associated haplotype, however,
ﬁve (two in speciﬁc, i.e., rs10838524 and rs3824872) were signiﬁcantly
associated with dysthymia, two (one in speciﬁc, i.e., rs7123390) with
major depressive disorder, and four (i.e., rs7121611, rs7945565,
rs1401419 and rs2292910) with depressive disorders (herein, dysthy-
mia, major depressive disorder, or both). To have an idea for a
mechanistic hypothesis of the impact of these genetic variants on the
clinical phenotypes, a search from a bioinformatics database
(HaploReg, v4.1, www.broadinstitute.org) yielded some information
about these SNPs as follows. CRY2 rs10838524 as an intronic SNP
inﬂuences the binding of the glucocorticoid receptor (NR3C1) which is
implicated in depressive disorders (Goodwin et al., 1992) and known to
interact reciprocally with CRY2 (Lamia et al., 2011; Torres-Farfan
et al., 2009), thus having an impact on physiology and possibly on
mood regulation as well. CRY2 rs10838524 also inﬂuences the binding
of the CCCTC-binding factor (CTCF) and may thereby have an eﬀect on
transcriptional regulation of CRY2.
With regard to PRKCDBP, this is the ﬁrst time that polymorphisms
within this gene are linked to depressive disorders. The protein has
earlier been shown to aﬀect circadian clock functions (Schneider et al.,
2012): PER2 complex interacts with PRKCDBP, and PER-to-CRY
protein abundance and interactions are aﬀected by PRKCDBP. In
addition, the circadian period length is inﬂuenced by PRKCDBP such
that the loss-of function shortened the period (Schneider et al., 2012),
similar to knockout animal models of each key clock gene except that of
Cry2 (Ko and Takahashi, 2006). Cry2 knockout mice have a prolonged
circadian period which as such resembles the gain-of-function for
PRKCDBP that is the lengthened circadian period. A search from the
aforementioned bioinformatics database yielded that PRKCDBP
rs1488864 inﬂuences the binding of 10 proteins, among them
NFKB1 which is known to interact with cryptochromes (Lee and
Sancar, 2011; Narasimamurthy et al., 2012) and implicated in depres-
sive disorders (Miklowitz et al., 2016) but with conﬂicting data (Mellon
et al., 2016), and BCL11A which is relevant to a characterized at-risk
phenotype for anxiety and depressive disorders (Alisch et al., 2014).
Our study has several strengths. We based our study on a large
random sample representative of the Finnish adult population and its
11-year follow-up data. The diagnoses of mental health were assessed
with a structured and validated diagnostic interview method which
yielded reliable diagnoses of depressive disorders based on the DSM-IV
classiﬁcation. We had well-covered genetic information for variants in
both cryptochrome genes and SDPR gene. We applied strict multiple
statistical testing correction by the false-discovery rate method. Despite
the increased number of cases from the follow-up, Finland is still a
relatively small country by population and therefore the number of
cases remains moderate. Further, some SNPs in PRKCDB were not
successfully included in the genotyping multiplexes.
To conclude, our study supports the role of CRY2 in depressive
disorders and reports a novel association of PRKCDBP with major
depressive disorder.
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